Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure (NCT03500731)

The primary purpose of the study is to evaluate the safety and efficacy of performing lung transplantation followed by cadaveric, partially HLA-matched (≥1/6 HLA-match with an identical ABO blood type) CD3+/CD19+ depleted bone marrow transplantation in bone marrow failure and end-stage lung disease. This protocol focuses on performing combined transplantation for candidates that are unable to undergo standard lung transplantation.

Lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, and to restore hematologic function post BMT transplantation.

Initiated by the UPMC Immune Transplant and Therapy Center.

Trial Eligibility

This study is open to adult patients between the ages of 18 and 60. For additional requirements and criteria please visit ClinicalTrials.gov.

Study Start Date: April 19, 2018
Estimated Primary Completion Date: December 2023
Estimated Study Completion Date: December 2026

Learn more about this trial on its clinicaltrials.gov page or contact Shawna McIntyre, BSN, RN, at mcintyresm@upmc.edu or 412-692-5552.

Lab Team

Principal Investigators:
Paul Szabolcs, MD
John McDyer, MD
Annie Im, MD
Mounzer Agha, MD
Jonathan D’Cunhna, MD